Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in HIV-infected adults previously vaccinated w1ith pneumococcal polysaccharide vaccine

Journal of Infectious Diseases

Volumn 212, Issue 1, 2015, Pages 18-27

  Glesby, Marshall J ^a   Watson, Wendy ^b   Brinson, Cynthia ^c   Greenberg, Richard N ^d   Lalezari, Jacob P ^e   Skiest, Daniel ^f   Sundaraiyer, Vani ^g   Natuk, Robert ^b   Gurtman, Alejandra ^b   Scott, Daniel A ^b   Emini, Emilio A ^b   Gruber, William C ^b   Schmoele Thoma, Beate ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b PFIZER INC   (United States)

^c Central Texas Clinical Research   (United States)

^d UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^e Quest Clinical Research   (United States)

^f BAYSTATE MEDICAL CENTER   (United States)

^g SYNEOS HEALTH   (United States)

Author keywords

adult; Human immunodeficiency virus; immunogenicity; pneumococcal conjugate vaccine; pneumococcal polysaccharide vaccine.

Indexed keywords

ANTIRETROVIRUS AGENT; IMMUNOGLOBULIN G ANTIBODY; PNEUMOCOCCUS VACCINE; 13-VALENT PNEUMOCOCCAL VACCINE; BACTERIUM ANTIBODY; IMMUNOGLOBULIN G; OPSONIN;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ARTICLE; BRONCHITIS; CD4 LYMPHOCYTE COUNT; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; OPEN STUDY; OPSONOPHAGOCYTOSIS; PHAGOCYTOSIS; PHASE 3 CLINICAL TRIAL; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; RASH; SINGLE DRUG DOSE; UPPER RESPIRATORY TRACT INFECTION; VACCINATION; VIRUS LOAD; VOMITING; AGED; BLOOD; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; SERUM BACTERICIDAL ACTIVITY; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, BACTERIAL; BLOOD BACTERICIDAL ACTIVITY; CD4 LYMPHOCYTE COUNT; FEMALE; HIV; HIV INFECTIONS; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; OPSONIN PROTEINS; PHAGOCYTOSIS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; VIRAL LOAD; YOUNG ADULT;

EID: 84936817271     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu631     Document Type: Article

References (44)

1. Bliss SJ, O'Brien KL, Janoff EN, et al. The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease. Lancet Infect Dis 2008; 8:67-80.
2. Cohen AL, Harrison LH, Farley MM, et al. Prevention of invasive pneumococcal disease among HIV-infected adults in the era of childhood pneumococcal immunization. AIDS 2010; 24:2253-62.
3. Yin Z, Rice BD, Waight P, et al. Invasive pneumococcal disease among HIV-positive individuals, 2000-2009. AIDS 2012; 26:87-94.
4. Wolter N, Cohen C, Tempia S, et al. HIV and influenza virus infections are associated with increased blood pneumococcal load: a prospective, hospital-based observational study in South Africa, 2009-2011. J Infect Dis 2014; 209:56-65.
5. McEllistrem MC, Mendelsohn AB, Pass MA, et al. Recurrent invasive pneumococcal disease in individuals with human immunodeficiency virus infection. J Infect Dis 2002; 185:1364-8.
6. World Health Organization. HIV/AIDS treatment and care: clinical protocols for the WHO European Region. http://www.euro.who.int/-data/assets/pdf-file/0004/78106/E90840.pdf. Accessed 1 April 2013.
7. Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1-207; quiz CE1-4.
8. CDC. ACIP Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 2010; 59:1102-6.
9. French N, Nakiyingi J, Carpenter LM, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: doubleblind, randomised and placebo controlled trial. Lancet 2000; 355:2106-11.
10. Pedersen RH, Lohse N, Ostergaard L, Sogaard OS. The effectiveness of pneumococcal polysaccharide vaccination in HIV-infected adults: a systematic review. HIV Med 2011; 12:323-33.
11. Hung CC, Chen MY, Hsieh SM, Hsiao CF, Sheng WH, Chang SC. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study. Vaccine 2004; 22:2006-12.
12. Hung CC, Chang SY, Su CT, et al. A 5-year longitudinal follow-up study of serological responses to 23-valent pneumococcal polysaccharide vaccination among patients with HIV infection who received highly active antiretroviral therapy. HIV Med 2009; 11:54-63.
13. Rodriguez-Barradas MC, Alexandraki I, Nazir T, et al. Response of human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy to vaccination with 23-valent pneumococcal polysaccharide vaccine. Clin Infect Dis 2003; 37:438-47.
14. Lopez-Palomo C, Martin-Zamorano M, Benitez E, et al. Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination. J Med Virol 2004; 72:517-24.
15. Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003; 349:1341-8.
16. French N, Gordon SB, Mwalukomo T, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010; 362:812-22.
17. Feikin DR, Elie CM, Goetz MB, et al. Specificity of the antibody response to the pneumococcal polysaccharide and conjugate vaccines in human immunodeficiency virus-infected adults. Clin Diagn Lab Immunol 2004; 11:137-41.
18. Crum-Cianflone NF, Huppler Hullsiek K, Roediger M, et al. A randomized clinical trial comparing revaccination with pneumococcal conjugate vaccine to polysaccharide vaccine among HIV-infected adults. J Infect Dis 2010; 202:1114-25.
19. Feikin DR, Elie CM, Goetz MB, et al. Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. Vaccine 2001; 20:545-53.
20. Chen M, Ssali F, Mulungi M, et al. Induction of opsonophagocytic killing activity with pneumococcal conjugate vaccine in human immunodeficiency virus-infected Ugandan adults. Vaccine 2008; 26:4962-8.
21. Lesprit P, Pedrono G, Molina JM, et al. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS 2007; 21:2425-34.
22. Lu CL, Hung CC, Chuang YC, et al. Comparison of serologic responses to vaccination with one dose or two doses of 7-valent pneumococcal conjugate vaccine in HIV-infected adult patients. Vaccine 2012; 30:3526-33.
23. Lu CL, Hung CC, Chuang YC, et al. Serologic response to primary vaccination with 7-valent pneumococcal conjugate vaccine is better than with 23-valent pneumococcal polysaccharide vaccine in HIV-infected patients in the era of combination antiretroviral therapy. Hum Vaccin Immunother 2013; 9:398-404.
24. Miiro G, Kayhty H, Watera C, et al. Conjugate pneumococcal vaccine in HIV-infected Ugandans and the effect of past receipt of polysaccharide vaccine. J Infect Dis 2005; 192:1801-5.
25. Penaranda M, Payeras A, Cambra A, Mila J, Riera M; Majorcan Pneumococcal Study Group. Conjugate and polysaccharide pneumococcal vaccines do not improve initial response of the polysaccharide vaccine in HIV-infected adults. AIDS 2010; 24:1226-8.
26. Slayter KL, Singer J, Lee TC, Kayhty H, Schlech WF. Immunization against pneumococcal disease in HIV-infected patients: conjugate versus polysaccharide vaccine before or after reconstitution of the immune system (CTN-147). Int J STD AIDS 2013; 24:227-31.
27. Sogaard OS, Lohse N, Harboe ZB, et al. Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a Tolllike receptor 9 agonist adjuvant: a randomized, controlled trial. Clin Infect Dis 2010; 51:42-50.
28. Ho YL, Brandao AP, de Cunto Brandileone MC, Lopes MH. Immunogenicity and safety of pneumococcal conjugate polysaccharide and free polysaccharide vaccines alone or combined in HIV-infected adults in Brazil. Vaccine 2013; 31:4047-53.
29. Nunes MC, Madhi SA. Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals. Hum Vaccin Immunother 2012; 8:161-73.
30. CDC. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61:816-9.
31. Australian Technical Advisory Group on Immunisation. Pneumococcal disease recommendations. In: The Australian immunisation handbook. 10th ed. Canberra: Australian Government Department of Health, 2013.
32. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58:309-18.
33. Wernette CM, Frasch CE, Madore D, et al. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol 2003; 10:514-9.
34. Jackson LA, Neuzil KM. Pneumococcal polysaccharide vaccines. In: Plotkin SA, OrensteinWA, Offit PA, eds. Vaccines. 5th ed. Philadelphia, PA: Saunders, Elsevier, 2008.
35. Cooper D, Yu X, Sidhu M, Nahm MH, Fernsten P, Jansen KU. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. Vaccine 2011; 29:7207-11.
36. Jackson LA, Gurtman A, van Cleeff M, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine 2013; 31:3577-84.
37. Jackson LA, Gurtman A, van Cleeff M, et al. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine 2013; 31:3594-602.
38. Rabian C, Tschope I, Lesprit P, et al. Cellular CD4 T cell responses to the diphtheria-derived carrier protein of conjugated pneumococcal vaccine and antibody response to pneumococcal vaccination in HIV-infected adults. Clin Infect Dis 2010; 50:1174-83.
39. Gruber WC, Scott DA, Emini EA. Development and clinical evaluation of Prevnar 13, a 13-valent pneumocococcal CRM197 conjugate vaccine. Ann N Y Acad Sci 2012; 1263:15-26.
40. Tasker SA, Wallace MR, Rubins JB, Paxton WB, O'Brien J, Janoff EN. Reimmunization with 23-valent pneumococcal vaccine for patients infected with human immunodeficiency virus type 1: clinical, immunologic, and virologic responses. Clin Infect Dis 2002; 34: 813-21.
41. Lu CL, Chang SY, Chuang YC, et al. Revaccination with 7-valent pneumococcal conjugate vaccine elicits better serologic response than 23-valent pneumococcal polysaccharide vaccine in HIV-infected adult patients who have undergone primary vaccination with 23-valent pneumococcal polysaccharide vaccine in the era of combination antiretroviral therapy. Vaccine 2014; 32:1031-5.
42. Jackson LA, Gurtman A, Rice K, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2013; 31:3585-93.
43. Brice GT, Dobano C, Sedegah M, et al. Extended immunization intervals enhance the immunogenicity and protective efficacy of plasmid DNA vaccines. Microbes Infect 2007; 9:1439-46.
44. Torling J, Hedlund J, Konradsen HB, Ortqvist A. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. Vaccine 2003; 22: 96-103.